|
|
Post by notamnkdmillionaire on Apr 30, 2015 17:12:36 GMT -5
|
|
|
|
Post by liane on Apr 30, 2015 17:17:54 GMT -5
Like this comment:
LA Times - Please stop being a mouth piece for Wall Street short sellers. Afrezza, inhalable insulin,is a new type of treatment for diabetes, it will take time for doctors to get comfortable with prescribing it. Considering Afrezza has been on the market for less than 2 months, €1,000,000 in initial revenues a great start. Good things come to those who wait.
John Kastanes
at 2:39 PM April 30, 2015
|
|
|
|
Post by james on Apr 30, 2015 18:21:04 GMT -5
“There are well known and understood reasons for this, which we are in the process of correcting,” he said. “The first quarter was also only a partial quarter. ... The second quarter will be much more telling, as will the third. What we need to see is the trend.”
Well - not that it's the time scale he's referring to, but the current trend has flattened out considerably. Would certainly help to know what they consider the reasons for slow initial sales. We talk about these things on the board, but it would be helpful to get more on that view from the company. I don't expect it...
|
|
|
|
Post by compound26 on Apr 30, 2015 18:31:52 GMT -5
It could be that SNY has so far only reached out to a very small number of endos, which has resulted the flattening of the growth curve. A Sanofi spokeswoman said that the initial rollout of Afrezza was “ targeted and focused” on building awareness about the product and appropriate usage. It will take time for the drug to demonstrate its potential. MannKind and Sanofi plan to launch a direct-to-consumer campaign this year. www.valuewalk.com/2015/04/mannkinds-afrezza-q1-sales-sanofi/ |
|
|
|
Post by notamnkdmillionaire on Apr 30, 2015 18:41:54 GMT -5
“There are well known and understood reasons for this, which we are in the process of correcting,” he said. “The first quarter was also only a partial quarter. ... The second quarter will be much more telling, as will the third. What we need to see is the trend.” Well - not that it's the time scale he's referring to, but the current trend has flattened out considerably. Would certainly help to know what they consider the reasons for slow initial sales. We talk about these things on the board, but it would be helpful to get more on that view from the company. I don't expect it... The WWII saying, "loose lips sinks ships" was one to protect our country. In MNKD's case, staying silent is sinking the USS MNKD on Nasdaq. Mannkind could really use its own OSS (pre CIA) to sabotage those wreaking havoc on the stock. |
|
|
|
Post by gamblerjag on Apr 30, 2015 20:20:04 GMT -5
Lianne. I didn't see that quote in the article.. where was Matt's quote?
|
|
|
|
Post by liane on Apr 30, 2015 20:28:13 GMT -5
gambler,
It's a comment to the article - look to the lower right, and click on "all comments".
|
|
